Literature DB >> 22571402

Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles.

A Lalatsa1, N L Garrett, T Ferrarelli, J Moger, A G Schätzlein, I F Uchegbu.   

Abstract

The clinical development of therapeutic peptides has been restricted to peptides for non-CNS diseases and parenteral dosage forms due to the poor permeation of peptides across the gastrointestinal mucosa and the blood-brain barrier. Quaternary ammonium palmitoyl glycol chitosan (GCPQ) nanoparticles facilitate the brain delivery of orally administered peptides such as leucine(5)-enkephalin, and here we examine the mechanism of GCPQ facilitated oral peptide absorption and brain delivery. By analyzing the oral biodistribution of radiolabeled GCPQ nanoparticles, the oral biodistribution of the model peptide leucine(5)-enkephalin and coherent anti-Stokes Raman scattering microscopy tissue images after an oral dose of deuterated GCPQ nanoparticles, we have established a number of facts. Although 85-90% of orally administered GCPQ nanoparticles are not absorbed from the gastrointestinal tract, a peak level of 2-3% of the oral GCPQ dose is detected in the blood 30 min after dosing, and these GCPQ particles appear to transport the peptides to the blood. Additionally, although peptide loaded nanoparticles from low (6 kDa) and high (50 kDa) molecular weight GCPQ are taken up by enterocytes, polymer particles with a polymer molecular weight greater than 6 kDa are required to facilitate peptide delivery to the brain after oral administration. By examining our current and previous data, we conclude that GCPQ particles facilitate oral peptide absorption by protecting the peptide from gastrointestinal degradation, adhering to the mucus to increase the drug gut residence time and transporting GCPQ associated peptide across the enterocytes and to the systemic circulation, enabling the GCPQ stabilized peptide to be transported to the brain. Orally administered GCPQ particles are also circulated from the gastrointestinal tract to the liver and onward to the gall bladder, presumably for final transport back to the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571402     DOI: 10.1021/mp300068j

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  8 in total

Review 1.  Penetration of the blood-brain barrier by peripheral neuropeptides: new approaches to enhancing transport and endogenous expression.

Authors:  M R Lee; R D Jayant
Journal:  Cell Tissue Res       Date:  2018-12-10       Impact factor: 5.249

Review 2.  Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer.

Authors:  Annette Bak; Dennis Leung; Stephanie E Barrett; Seth Forster; Ellen C Minnihan; Andrew W Leithead; James Cunningham; Nathalie Toussaint; Louis S Crocker
Journal:  AAPS J       Date:  2014-11-15       Impact factor: 4.009

3.  Glycol-Chitosan-Based Technetium-99m-Loaded Multifunctional Nanomicelles: Synthesis, Evaluation, and In Vivo Biodistribution.

Authors:  Nashmia Zia; Zafar Iqbal; Abida Raza; Aadarash Zia; Rabia Shafique; Saiqa Andleeb; Gilbert C Walker
Journal:  Nanomaterials (Basel)       Date:  2022-06-27       Impact factor: 5.719

4.  Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease.

Authors:  Nan Jiang; Leonie H E Leithold; Julia Post; Tamar Ziehm; Jörg Mauler; Lothar Gremer; Markus Cremer; Elena Schartmann; N Jon Shah; Janine Kutzsche; Karl-Josef Langen; Jörg Breitkreutz; Dieter Willbold; Antje Willuweit
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

5.  Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.

Authors:  Funmilola A Fisusi; Adeline Siew; Kar Wai Chooi; Omotunde Okubanjo; Natalie Garrett; Katerina Lalatsa; Dolores Serrano; Ian Summers; Julian Moger; Paul Stapleton; Ronit Satchi-Fainaro; Andreas G Schätzlein; Ijeoma F Uchegbu
Journal:  Pharm Res       Date:  2016-02-22       Impact factor: 4.200

Review 6.  Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting.

Authors:  Maria Cristina Bonferoni; Elisabetta Gavini; Giovanna Rassu; Marcello Maestri; Paolo Giunchedi
Journal:  Nanomaterials (Basel)       Date:  2020-04-30       Impact factor: 5.076

7.  Preformulation Studies of a Stable PTEN-PDZ Lipopeptide Able to Cross an In Vitro Blood-Brain-Barrier Model as a Potential Therapy for Alzheimer's Disease.

Authors:  Aikaterini Lalatsa; Yujiao Sun; Jose Ignacio Gamboa; Shira Knafo
Journal:  Pharm Res       Date:  2020-09-04       Impact factor: 4.200

8.  Harnessing the Antibacterial Properties of Fluoridated Chitosan Polymers against Oral Biofilms.

Authors:  Dien Puji Rahayu; Roger Draheim; Aikaterini Lalatsa; Marta Roldo
Journal:  Pharmaceutics       Date:  2022-02-23       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.